Medical device manufacturers face a fundamental challenge that most enterprise AI deployments don't: they rarely need a single approach to serve every workflow in their organization. A design-control assistant, a submission-authoring tool, and a post-market surveillance application operate on entirely different evidence requirements, failure consequences, and regulatory constraints. This reality is forcing MedTech teams to get surgical about which AI pattern fits which use case—and the decisions are more nuanced than simply picking the "best" model.

The Four Approaches in Play

The article breaks down four distinct deployment strategies that medical device companies are actively evaluating: Retrieval-Augmented Generation (RAG), fine-tuning, autonomous agents, and rules-based systems. Each approach carries different implications for traceability, validation burden, and regulatory compliance—factors that matter enormously when FDA audits or customer safety incidents force you to explain every output your system produced.

RAG vs Fine-Tuning: The Knowledge Problem

RAG allows organizations to keep their proprietary documentation, design history files, and standard operating procedures outside the model's weights while still leveraging them at inference time. This makes it attractive for submission-authoring workflows where you need the model to reference specific regulatory language or your company's existing technical files without risking hallucinations about internal processes. Fine-tuning, by contrast, bakes knowledge into the model itself—which creates better consistency but introduces re-validation requirements every time you update the training data.

Agents and Rules: Handling High-Stakes Decisions

Autonomous agents excel at multi-step workflows that require the AI to make decisions, call tools, and iterate toward a goal—think automated CAPA investigations or complaint triage pipelines. But for regulated applications where every decision path must be auditable, many teams are finding that pure agentic approaches introduce too much unpredictability. Rules-based systems remain surprisingly relevant here: when failure consequences are severe and the logic is well-understood, explicit if-this-then-that guards provide the deterministic audit trails that regulators expect.

Matching Patterns to Risk Profiles

The core insight emerging from this analysis is that MedTech AI deployment isn't a one-size-fits-all architecture question. Design-control assistants might thrive with fine-tuned models trained on your quality management system's historical decisions, while post-market surveillance may need RAG's ability to query vast complaint databases in real-time without retraining. The teams succeeding are treating these as separate engineering problems requiring different evaluation criteria—not as variations of a single implementation.

Key Takeaways

  • RAG keeps data external and auditable; fine-tuning bakes knowledge in but increases validation overhead when updated
  • Agents handle complex multi-step workflows but introduce unpredictability that regulators may question
  • Rules-based systems remain the gold standard for high-stakes, deterministic decision paths requiring full audit trails
  • Medical device manufacturers should evaluate each workflow's risk profile and regulatory exposure before choosing an AI pattern

The Bottom Line

The MedTech industry is learning what other regulated sectors are slowly discovering: generative AI isn't a single tool to deploy—it's a category of approaches that need to be matched to specific use cases based on traceability requirements, validation burden, and failure consequences. Teams that treat this as an architectural decision rather than a model selection problem will ship compliant systems faster.